FREDERICK PEARSON SMITH M.D. NPI 1730185935

NPI Details

Frederick Pearson Smith, M.D. is a medical oncology internal medicine in Chevy Chase, MD with 53 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Frederick Pearson Smith, M.D. NPI is 1730185935. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

5454 WISCONSIN AVE
STE 1300
CHEVY CHASE, MD
ZIP 20815-908
Phone: (301) 657-4588
Fax: (301) 657-9565

The NPI 1730185935 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The CLIA number assigned to this NPI record is 21D2119640 - physician office with a certificate type of Certificate of Compliance.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Unclassified drugs (HCPCS:J3490)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection of drug or substance into vein (HCPCS:96374)

The enumeration date for this NPI number is 6/22/2005 and was last updated on 9/8/2010.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.